We are live on ! Find out more
VYGR icon

Voyager Therapeutics

138 hedge funds and large institutions have $430M invested in Voyager Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,285% more call options, than puts

Call options by funds: $830K | Put options by funds: $13K

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

18% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 40

5% more funds holding

Funds holding: 131138 (+7)

0.17% more ownership

Funds ownership: 83.06%83.23% (+0.17%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

19% less capital invested

Capital invested by funds: $528M → $430M (-$98M)

Holders
138
Holders Change
+7
Holders Change %
+5.34%
% of All Funds
2.72%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
47
Reduced
40
Closed
18
Calls
$830K
Puts
$13K
Net Calls
+$817K
Net Calls Change
-$839K
Name Holding Trade Value Shares
Change
Change in
Stake
MIM
101
MetLife Investment Management
New Jersey
$149K
Simplex Trading
102
Simplex Trading
Illinois
$147K +$59.6K +4,099 +63%
UBS Group
103
UBS Group
Switzerland
$145K -$1.25M -86,264 -89%
Nisa Investment Advisors
104
Nisa Investment Advisors
Missouri
$142K
Mitsubishi UFJ Asset Management
105
Mitsubishi UFJ Asset Management
Japan
$141K +$62K +4,264 +68%
PP
106
PDT Partners
New York
$141K +$146K +10,078 New
FQ
107
First Quadrant
California
$138K -$51.8K -3,562 -27%
Group One Trading
108
Group One Trading
Illinois
$127K +$132K +9,087 New
MLICM
109
Metropolitan Life Insurance Company (MetLife)
New York
$126K
JWM
110
Jackson Wealth Management
Florida
$120K +$145K +10,000 New
AL
111
AJO LP
Pennsylvania
$118K +$123K +8,462 New
PAM
112
Panagora Asset Management
Massachusetts
$116K +$8.42K +579 +7%
Royal Bank of Canada
113
Royal Bank of Canada
Ontario, Canada
$95K +$25.9K +1,783 +36%
Victory Capital Management
114
Victory Capital Management
Texas
$86K +$28.4K +1,954 +46%
Rockefeller Capital Management
115
Rockefeller Capital Management
New York
$83K -$1.19K -82 -1%
NIT
116
NumerixS Investment Technologies
British Columbia, Canada
$80K -$50.9K -3,500 -38%
Macquarie Group
117
Macquarie Group
Australia
$80K
Legal & General Group
118
Legal & General Group
United Kingdom
$79K +$13.3K +915 +19%
SPIA
119
Steward Partners Investment Advisory
New York
$60K +$48.7K +3,350 +335%
BNP Paribas Financial Markets
120
BNP Paribas Financial Markets
France
$38.8K -$11K -755 -21%
HPC
121
HM Payson & Co
Maine
$32K
Zurich Cantonal Bank
122
Zurich Cantonal Bank
Switzerland
$30K
AIP
123
Ameritas Investment Partners
Nebraska
$28K
RA
124
Royce & Associates
New York
$21K +$1.69K +116 +8%
Canada Life
125
Canada Life
Manitoba, Canada
$20K +$21.2K +1,458 New

VYGR Hedge Fund Activity: Q4 2019 in Review

138 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2019, worth a combined $430M — down 19% from $528M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VYGR positions and 18 closed out — a net gain of 8 holders — while 47 added to existing stakes and 40 trimmed.

The largest buyer was Armistice Capital, adding an estimated $7.67M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $21.2M sold.

  • 138 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2019, up from 131 in Q3 2019.
  • Funds reported $430M of Voyager Therapeutics stock for Q4 2019, down 19% quarter-over-quarter.
  • 26 funds opened new Voyager Therapeutics positions in Q4 2019 and 18 closed out, a net change of +8 holders.
  • The largest Voyager Therapeutics buyer in Q4 2019 was Armistice Capital, an estimated $7.67M added.
  • The largest Voyager Therapeutics seller in Q4 2019 was PFM Health Sciences, an estimated $21.2M sold.

Based on aggregated 13F filings for Q4 2019.